TABLE 3.
Studies reporting the combined effects of space environment in human cells.
| Studied materials | Experimental treatments | Combined biological effects | Refs |
|---|---|---|---|
| Human peripheral blood lymphocytes | γ-rays (0.2, 2 Gy) + RWV (4, 24 h) | Decreased number of radio-responsive miRNAs | Girardi et al. (2012) |
| Human lymphocytes | X-rays/protons (1–6 Gy) + RWV (24 h) | No effect on CA | Manti et al. (2005) |
| Human fibroblast 1BR-hTERT cells | X-rays/carbon ions (0.5, 1.5 Gy)-3D clinostat (24 h) | Increased CA | Hada et al. (2019) |
| Human lymphoblastic TK6 cells | X-rays/carbon ions (0.5, 1.5 Gy)-3D clinostat (24 h) | Increased CA | Yamanouchi et al. (2020) |
| Human lymphocytes | X-rays (1.5 Gy) + cuvette clinostat (2 h) | Increased CA | Mosesso et al. (2001) |
| Human peripheral blood lymphocytes | γ-rays (5 Gy) + RWV (0.5, 2, 6, 24 h) | Decreased DNA damage repair | Mognato et al. (2009) |
| Human skin fibroblast NHF-23 cells | X-rays (5, 10 Gy) + real microgravity (4.5 h) | No effect on DNA damage repair | Horneck et al. (1996) |
| Human lymphoblastoid TK6 cells | γ-rays (1, 2, 4 Gy) + RWV (24 h) | Decreased apoptosis | Canova et al. (2005) |
| Human B lymphoblastoid HMy2.CIR cells | RWV (30 min) + carbon ions (0.2, 0.4, 0.6, 0.8 Gy) | Increased cell survival and apoptosis | Dang et al. (2014) |
| Human peripheral blood lymphocytes | X-rays/γ-rays (1, 2 Gy) + RWV (24 h) | Increased HPRT mutation frequency | Mognato and Celotti (2005) |
| Human fibroblasts 1BR-hTERT cells | X-rays/carbon ions (1 Gy, 0.03 Gy/min)-3D clinostat (48 h) | DNA damage and failure of cell cycle checkpoint block | Ikeda et al. (2019) |
| Human lymphoblast TK6 cells | γ-rays (2 Gy) + RWV (24 h) | Additive/synergistic effects on RNA expression patterns/levels | Fu et al. (2020) |
| Human lung epithelial cells BEAS-2B | 3D clinostat (48 h) + X-rays (2 Gy) | Increased DNA damage, apoptosis and RAC2 expression and inhibition of proliferation and survival additively | Tan et al. (2020) |
“+”: sequential treatments; “-”: simultaneous treatments.